Suven Life Sciences P/E Ratio
Suven Life Sciences P/E ratio. Suven Life Sciences (SUVEN) P/E ratio is not applicable — EPS (TTM) ₹-12.13, 8 consecutive loss quarters. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company has been reporting losses for 8 consecutive quarters. P/E ratio cannot be calculated for loss-making companies.
Consecutive Loss Quarters: 8
Current EPS: ₹-12.13
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | -2.02 | -46 | Loss |
| Jun 2026 | -4.84 | -128 | Loss |
| Sept 2025 | -3.48 | -77 | Loss |
| Mar 2025 | -2.02 | -44 | Loss |
| Jun 2025 | -2.36 | -52 | Loss |
| Dec 2025 | -4.55 | -102 | Loss |
| Sept 2024 | -2.27 | -50 | Loss |
| Mar 2024 | -1.22 | -27 | Loss |
Healthcare Peers with Valid P/E Ratios — SUVEN Comparison
Healthcare sector average P/E 56.31, median 32.41 — SUVEN excluded (negative EPS).
Sector Average PE
56.31
Sector Median PE
32.41
Lowest PE
2.04
Profitable Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| GKB Ophthalmics | GKB | 6.27 | ₹33 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Suven Life Sciences share price screener.
- Examine Suven Life Sciences quarterly earnings for recent quarterly revenue, profit and EPS trends.
- Also explore SUVEN stock price history to track price trends across different timeframes.